Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
WNT signaling contributes to the extrahepatic bile duct proliferative response to obstruction in mice
Ashley N. Calder, … , Linda C. Samuelson, Nataliya Razumilava
Ashley N. Calder, … , Linda C. Samuelson, Nataliya Razumilava
Published December 5, 2024
Citation Information: JCI Insight. 2025;10(2):e181857. https://doi.org/10.1172/jci.insight.181857.
View: Text | PDF
Research Article Hepatology

WNT signaling contributes to the extrahepatic bile duct proliferative response to obstruction in mice

  • Text
  • PDF
Abstract

Biliary obstruction and cholangiocyte hyperproliferation are important features of cholangiopathies affecting the large extrahepatic bile duct (EHBD). The mechanisms underlying obstruction-induced cholangiocyte proliferation in the EHBD remain poorly understood. Developmental pathways, including WNT signaling, are implicated in regulating injury responses in many tissues, including the liver. To investigate the contribution of WNT signaling to obstruction-induced cholangiocyte proliferation in the EHBD, we used complementary in vivo and in vitro models with pharmacologic interventions and transcriptomic analyses. To model obstruction, we used bile duct ligation (BDL) in mice. Human and mouse biliary organoids and mouse biliary explants were used to investigate the effects of WNT activation and inhibition in vitro. We observed an upregulation of WNT ligand expression associated with increased biliary proliferation following obstruction. Cholangiocytes were identified as both WNT ligand–expressing and WNT-responsive cells. Inhibition of WNT signaling decreased cholangiocyte proliferation in vivo and in vitro, while activation increased proliferation. WNT effects on cholangiocyte proliferation were β-catenin dependent, and we showed a direct effect of WNT7B on cholangiocyte growth. Our studies suggested that cholangiocyte-derived WNT ligands can activate WNT signaling to induce proliferation after obstructive injury. These findings implicate the WNT pathway in injury-induced cholangiocyte proliferation within the EHBD.

Authors

Ashley N. Calder, Mirabelle Q. Peter, John W. Tobias, Nureen H. Mohamad Zaki, Theresa M. Keeley, Timothy L. Frankel, Linda C. Samuelson, Nataliya Razumilava

×

Figure 5

Canonical WNT activation promotes cholangiocyte proliferation in mouse EHBD explants and mouse and human EHBD organoids.

Options: View larger image (or click on image) Download as PowerPoint
Canonical WNT activation promotes cholangiocyte proliferation in mouse E...
(A and B) Diagram of EHBD explant and organoid culturing protocols. (C) Timeline of EHBD explant experiment with 10 μM CHIR treatment. (D) EdU (green), KRT19 (red), and DAPI (blue) staining in explants. (E) Morphometric analysis of proliferation in biliary explants. (F and G) BIRC5 (green), KRT19 (red), and DAPI (blue) staining in explants and quantification. Asterisks indicate lumen, arrows indicate EdU+ and BIRC5+ cells. Scale bar: 50 μm. n = 3–5 mice/group. (H) Timeline of the experiment treating mouse and human biliary organoids with 3 μM CHIR. (I–K) Mouse organoid images (I), size (J), and viability (K) by measurement of culture ATP levels in vehicle- and CHIR-treated organoids.(L–N) Human organoid images (L), size (M), and viability (N) measurements in vehicle- and CHIR-treated organoids. n = 3 biological replicates. Scale bar: 500 μm. Size and viability measurements are normalized the vehicle controls. Two-way ANOVA with Bonferroni’s multiple-comparison test was used for morphometric analysis of EdU and BIRC5. Unpaired Student’s t test was used for organoid experiments. *P < 0.05, ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts